Hello and welcome to
this new issue of Leader’s Talk which is today focusing on
medical imaging solutions for diagnostic laboratories. The digital trasformation
of diagnostic laboratories is a key challenge
for cancer treatments. Current technologies, especially AI,
provide concrete answers to problems faced by laboratories, particularly in terms
of workload and complexity. However, only 5% of
pathology laboratories are equipped. In order to have a more details
on this medical imaging solutions I welcome our guest,
Jean-François Pomerol, CEO of TRIBVN Healthcare. – Hello!
– Hi, thanks for welcoming me. Thank you for being with us today.
Let’s begin the interview. Your area of expertise focuses
on pathology laboratories, can you explain
what is the role of pathologists? Pathologists are medical doctors, who diagnose complex diseases,
namely cancer. They do it by studying tissues
and cells under the microscope, and they have a key role in understanding
what is going on with complex diseases. It is essential in the context
of personalised medecine. Pathologists are asked to determine which therapy will offer the best
possible outcome for the patient. It is a question of medical
and economic efficiency. What to expect from
this market in the coming years? What are the trends? First, I will say that global activities
of pathology laboratories increase, we are talking about
5% each year. This can be explained by the fact that the total number of cancer
is increasing every year. Then, the complexity of the diagnosis is also increasing linked
with the personalised medecine I was talking about earlier. The second thing
I would say is that we are facing a global shortage
of pathologists worldwide, due to demographic reasons
in many countries and also due to the fact that
it takes time to train pathologists about 20 years of
training and practising. If you put all that together,
you can easily understand that pathology laboratories must change
the way they are doing diagnosis and cancer diagnosis. Digital imaging transformation,
what we call digital pahology, is a solution for that. So in this market, we expect
an amazing growth in the coming years, with a total market for digital pathology
above 1 billion dollars within 5 years. What do you mean precisely by digital
pathology applied to pathology labs? It is simply the capacity that we have
to get rid of the microscope and replacing it by a screen. So it is a combination of
different mature technologies, which are high resolution scanning,
high speed networks and important computational capacities
to manage these data because, just for you to know, one patient’s case
is about 10 GB of data and every lab going digital produces up to 5 TB of data each day,
it is really huge. It is a true challenge
to be able to manage that. What we know now
from early adopters is that it is not only about buying
a scanner or a screen, it is a complete redesign of your lab
or organisation of your processes. It is a new way of working and a new balance between
technicians and doctors, between pathologists and clinicians and also in relation with patients. You have to think at the global project,
global redesign of your organisation. What do these solutions
bring to the medical field to both health
professionals and patients? First, it is a way to work without having
the physical glass slide in hands so your work changes a lot,
because you can work remotely, you can work from home. you can organise telemedicine networks
with people who are far away. So the first advantage is that it is much easier to communicate
between pathologists. The second thing is that
once you get a biological file, you can use algorithms to detect,
to find, to count, to mesure, cells and cells abnormalities. So you enter the area
of AI applied to diagnosis, which means towards a diagnosis
helped by a computer. This possibility offers
numerous advantages for the pathology department,
it is a question of productivity gain you save the time
of technicians and pathologists. Recent studies have demonstrated that you can save up to 25%
of pathologists’ time which is huge if you think about
the challenge we talked about earlier. For patients, it is a guarantee to have
a more rapid and secure diagnosis, which is important
in complex therapies like cancer, and for social security,
healthcare insurer, it is a way to be sure
that expensive therapies will be more efficient to the patient and deliver the best possible outcomes. We understand well the situation
and what is at stake, but tell me more about
TRIBVN Healthcare solutions and what you are proposting
to pathology labs. TRIBVN Healthcare is a software company so we design and develop
software solutions for the digital transition
of laboratories. We have a complete suite to manage,
to share and to analyse medical images. It is a combination of
an easy to use and a fast viewer of powerful workflow management to deliver the right image
at the right time and in a secure way. It is, of course, a lot of
clinical applications, fueled by AI. We have many tool products. One is CaloPix,
for the daily lab organisation and one is TeleSlide, to organise collaborative activities
and networks over the Internet. Both products are highly configurable so we can address activities
in the diagnosis field but also in the educational
and research fields. Both products are medical devices
in Europe and in Canada, and we equipped more than 200 customers
in those areas with our solutions. Why do your customers
chose your company? What is your specificity on the market? We have been working
in this industry for many years. We are well recognised
as true specialists of the digital transformation
of laboratories, so, of course,
we have very good products and we develop them
with pathologists, but besides that, we are able to provide
lots of services around these products, like project management,
training, long-term support. We have a team with proven experience in transforming
the pathology organisation and we are able to provide
complete solutions to accompany them. I think that is something
quite unique on the market. You have just completed
a fundraising campaign. Why now and what are
the development axes you are working on? I am happy to talk about that because this is clearly
a new adventure for TRIBVN Healthcare. So far we were self-financed
but, as you understand, we expect a rising,
an acceleration in the market. We also truly believe that
our products, our offer brings tremendous value to the customer
and to the pathology department. We want to grow faster and we want to be at the forefront
of this digital pathology revolution. About one year ago,
we met many VCs and we are very happy
to have met and signed with LBO France, which manages the first European fund
dedicated to digital healthcare. They have a senior team with lots of
knowledge, experience in that field. The 5 million euros funding will be used to develop our commercial activities
in Europe and in North America. It will also be used to accelerate
our products’ roadmap. Just one example, I am very keen and happy
to share with you that we were just awarded
by Greater Paris region for the development
of a clinical AI application on digestive biopsies. That is clearly the kind of things
we want to do and a way, an approach
to make the buzz of AI and medical imaging a true reality
for pathologists, doctors and patients. Thank you for all these explanations
about your solutions in the market. Thank you. Thank you for being with us today. I shall see you soon
on a news Leader’s Talk TV program. Subtitles:
Alessandra ORLO